Journal of Neuro-Oncology

, Volume 81, Issue 2, pp 139–148

Expression of nine tumour antigens in a series of human glioblastoma multiforme: interest of EGFRvIII, IL-13Rα2, gp100 and TRP-2 for immunotherapy

  • Stéphan Saikali
  • Tony Avril
  • Brigitte Collet
  • Abderrahmane Hamlat
  • Jean-Yves Bansard
  • Bernard Drenou
  • Yvon Guegan
  • Véronique Quillien
Laboratory Investigation

DOI: 10.1007/s11060-006-9220-3

Cite this article as:
Saikali, S., Avril, T., Collet, B. et al. J Neurooncol (2007) 81: 139. doi:10.1007/s11060-006-9220-3
  • 456 Downloads

Abstract

In this study, we investigated the mRNA and protein expression of nine tumour antigens in human glioblastoma multiforme with a view to their possible use in dendritic cell-based immunotherapy. Expression of ALK, EGFRvIII, GALT3, gp100, IL-13Rα2, MAGE-A3, NA17-A, TRP-2 and tyrosinase were studied by real-time RT-PCR on frozen tissues using a series of 47 tumour samples from patients with glioblastoma. Results were compared with non-neoplastic brain expression or glioblastoma samples with very low levels of expression near the limits of detection for EGFRvIII and MAGE-A3, as these latter two antigens were not detected in non-neoplastic brain. Tumour antigens showing a 5-fold increase in mRNA expression were considered as positive, and only antigens displaying an mRNA over-expression in a significant number of cases were analysed by immunohistochemistry on paraffin-embedded sections. Using real time RT-PCR, we found EGFRvIII, gp100, IL-13Rα2 and TRP-2 to be positive in 64, 38, 32 and 21% of cases, respectively. While we observed no over-expression for ALK, GALT3 and tyrosinase, 3 samples out of 47 were positive for MAGE-3 and 1 sample for NA17-A. More than 25% of tumour cells showed strong protein expression in 13, 34, 85 and 96% of GBM samples for gp100, TRP-2, EGFRvIII and IL-13Rα2, respectively. Interestingly, protein expression of at least 3 antigens was observed in 38% of cases. These results point out the importance of EGFRvIII, IL-13Rα2 and, to a less extent gp100 and TRP-2, for developing an immunotherapy strategy against glioblastoma.

Keywords

Glioblastoma EGFRvIII gp100 IL-13Rα2 TRP-2 Dendritic cell-based immunotherapy 

Abbreviations

CTL

Cytotoxic T cell

GBM

Glioblastoma multiforme

MHC

Major histocompatibility complex

Copyright information

© Springer Science+Business Media B.V. 2006

Authors and Affiliations

  • Stéphan Saikali
    • 1
  • Tony Avril
    • 2
  • Brigitte Collet
    • 3
  • Abderrahmane Hamlat
    • 4
  • Jean-Yves Bansard
    • 5
  • Bernard Drenou
    • 6
  • Yvon Guegan
    • 4
  • Véronique Quillien
    • 7
  1. 1.Département d’Anatomie et cytologie pathologiquesHôpital PontchaillouRennesFrance
  2. 2.UPRES EA3889, Université de Rennes 1RennesFrance
  3. 3.Département de BiologieCentre Eugène MarquisRennesFrance
  4. 4.Département de NeurochirurgieHôpital PontchaillouRennesFrance
  5. 5.INSERM U642, Université de Rennes 1RennesFrance
  6. 6.Département d’HématologieHôpital E. MullerMulhouseFrance
  7. 7.Département de BiologieCentre Eugène Marquis, and UPRESRennesFrance

Personalised recommendations